STAT

JULY 28, 2023

A new Netflix TV show about the origins and consequences of the opioid epidemic is coming to the small screen. The show, “Painkiller,” is a fictional story based on real events that transpired around the Sackler family, Purdue Pharma, and the marketing and distribution of their drug, OxyContin. It adds to the growing list of television shows and movies around America’s opioid crisis, including Netflix’s own “The Pharmacist,” Hulu’s “Dopesic

246

246

PharmaVoice

JULY 28, 2023

Head honchos at the biggest pharma companies reporting second-quarter earnings dig into the topics du jour.

241

241

STAT

JULY 28, 2023

Canan Dagdeviren has dedicated her career to creating tools that can capture data from every nook and cranny of the human body. An electrode that reads brain signals in Parkinson’s patients. A tattoo-like patch to detect skin cancer. And now, a bra containing a flexible ultrasound that could one day be used to more comfortably screen for breast cancer.

246

246

BioPharma Dive

JULY 28, 2023

The British pharma is deepening its investment in genetic medicine through a deal for a group of Pfizer’s gene therapy delivery tools, while the New York giant cuts back.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JULY 28, 2023

For now, abortion remains accessible even in states where it’s banned — at least for those who know where to look. It’s still legal in two-thirds of the country, and numerous websites explain how to order medications from international pharmacies to end early pregnancies at home. But not all patients have equal access to reliable information.

236

236

Drug Patent Watch

JULY 28, 2023

Annual Drug Patent Expirations for SYMBICORT Symbicort is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. There are eleven patents protecting… The post New patent expiration for Astrazeneca drug SYMBICORT appeared first on DrugPatentWatch - Make Better Decisions.

98

98

The Pharmacist

JULY 28, 2023

The government has proposed updates to a scheme controlling the cost of branded medicines that it says will help protect medicines supply and keep prices competitive. It has launched a consultation on the statutory scheme to control the cost of branded health service medicines. But the body representing the pharmaceutical industry has criticised the proposals. […] The post Will proposed updates to statutory branded medicines pricing scheme help protect medicine supply?

95

95

STAT

JULY 28, 2023

In the U.S., about 16%  of Black birthing people are immigrants. But even as the federal government and states take steps to improve national maternal health, particularly among Black birthing parents, many immigrant parents are left out of new policy initiatives to provide access to postpartum care. Worsening maternal health in the U.S. and stark racial disparities have set in motion new policy efforts to increase access to postpartum care during the year following childbirth.

212

212

The Pharmacist

JULY 28, 2023

This summer’s pass rate for the common registration assessment for pharmacists was the lowest since 2020, according to figures released today. Just over three-quarters (77%) of the 2,805 candidates passed the assessment held in June by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI). The 2023 pass rate was below the […] The post Summer registration pass rate lowest in three years appeared first on The Pharmacist.

90

90

STAT

JULY 28, 2023

Biogen on Friday said it would acquire Reata Pharmaceuticals, the maker of an approved therapy for a rare neurological condition, in a deal worth $7.3 billion. The transaction price of $172.50 per share is a nearly 60% premium from Reata’s share price at Thursday’s close. The deal is expected to close by the end of the year. Reata, based in Plano, Texas, won its first approval in February for a drug that treats Friedreich’s ataxia.

212

212

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Patent Watch

JULY 28, 2023

A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020. The study… The post Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations appeared first on DrugPatentWatch - Make Better Decisions.

97

97

STAT

JULY 28, 2023

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to take in a football match, catch up on our reading, and promenade with the official mascots. And if time permits, we may hold a listening party, where the rotation would include this , this , this and this.

211

211

BioPharma Dive

JULY 28, 2023

The deal is a major bet by Biogen and its new CEO Chris Viehbacher, who’s reorganized R&D, cut costs and laid off staff since becoming company head last year.

98

98

STAT

JULY 28, 2023

Virtual mental health company Talkspace on Thursday added to its run of promising earnings reports, with the once-embattled company continuing to project it would break even by early 2024. Analyst groups like William Blair nodded along approvingly at Talkspace’s latest “step in the right direction” as the company, whose main business is providing therapy over text chat and audio and video connections, beat expectations by posting $35.6 million in revenue, for a $4.7 million

185

185

European Pharmaceutical Review

JULY 28, 2023

Publication of results of the Phase III SKYLARK study “is a pinnacle moment in treating postpartum depression ( PDD ),” stated Dr Kristina M Deligiannidis, Professor at the Institute of Behavioral Science at the Feinstein Institutes, the trial’s principal investigator, lead author of the paper. The study investigated oral 50mg, 14-day neuroactive steroid zuranolone pill as a treatment for perinatal or postpartum depression.

90

90

STAT

JULY 28, 2023

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them.  Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

180

180

BioPharma Dive

JULY 28, 2023

The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.

98

98

European Pharmaceutical Review

JULY 28, 2023

AstraZeneca has announced that Sharon Barr will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D. Pangalos will step down from his role in early 2024 due to retirement. His length of service with the company totals almost fourteen years. Sharon Barr brings over 18 years of industry experience into her new role and will be responsible for discovery through to late-stage development.

83

83

Pharmaceutical Technology

JULY 28, 2023

NS Pharma’s candidate would be the first to target Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping therapy.

98

98

PharmExec

JULY 28, 2023

Pandemic preparedness and curbing PBMs among the pending legislation that will have to wait until after summer recess.

97

97

Pharma Times

JULY 28, 2023

Mage Biologics aims to progress a novel, orally administered monoclonal antibody - News - PharmaTimes

97

97

Pharmaceutical Commerce

JULY 28, 2023

CDMO’s Turku addition will span over 69,000 square feet and support the production of ATMPs.

98

98

Pharma Times

JULY 28, 2023

The vital second batch represents a critical step on the candidate’s pathway to regulatory approval - News - PharmaTimes

83

83

pharmaphorum

JULY 28, 2023

1000Farmacie Secures $25 Million in Series A Funding Nicole.

98

98

Pharmaceutical Commerce

JULY 28, 2023

The pharma and biotech exec will begin his role on Aug. 1.

98

98

pharmaphorum

JULY 28, 2023

After cutbacks, Biogen adds new drug with $7.3bn Reata buy Phil.

94

94

World Pharma News

JULY 28, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells - which play a key role in immune response - that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Immunity 58

Immunity Immunization 58

pharmaphorum

JULY 28, 2023

BMS feels the pain of Revlimid erosion, cutting forecasts Phil.

90

90

Putting Patients First Blog

JULY 28, 2023

NHC Webinar Briefing on Medical Devices & Technology Event Time: 12:00 - 1:30 p.m. ET Event Location: Virtual The National Health Council (NHC) invites you to register for the Briefing on Medical Devices & Technology webinar. Join fellow advocates to hear from leaders in the sector, including Medical Device Innovation Consortium (MDIC), Edwards Lifesciences, DexCom and B.

52

52

pharmaphorum

JULY 28, 2023

Collaborative perseverance to bring change to medicine access Mike.

86

86

Drug Patent Watch

JULY 28, 2023

Annual Drug Patent Expirations for PYRUKYND Pyrukynd is a drug marketed by Agios Pharms Inc and is included in one NDA. It is available from one supplier. There are seven… The post New patent for Agios Pharms drug PYRUKYND appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Putting Patients First Blog

JULY 28, 2023

NHC Virtual Webinar Briefing on Medical Devices & Technology Event Time: 12:00 - 1:30 p.m. ET Event Location: TBD Virtual The National Health Council (NHC) invites you to register for the Briefing on Medical Devices & Technology webinar. Join fellow advocates to hear from leaders in the sector, including Medical Device Innovation Consortium (MDIC), Edwards Lifesciences, DexCom and B.

52

52

Drug Patent Watch

JULY 28, 2023

Obeticholic acid is the generic ingredient in one branded drug marketed by Intercept Pharms Inc and is included in one NDA. There are ten patents protecting this compound. Drug patent… The post New tentative approval for Optimus Pharma drug obeticholic acid appeared first on DrugPatentWatch - Make Better Decisions.

Compounding 52

Compounding 52

Proxsys Rx

JULY 28, 2023

(Photo above: St. Vincent’s Birmingham, one of ProxsysRx’s smaller pharmacies) The Retail Component “Dawn Dobersztyn does not get enough credit,” says ProxsysRx COO Billy Calhoun. “When you think about it, retail is the face of our pharmacies. It’s the first thing people see when they walk in the door. And here’s the thing: Everyone thinks they’re a retail expert.

Hospitals 52

Hospitals 52

RX Note

JULY 28, 2023

Introduction A drug administered parenterally is one injected via a hollow needle into the body at various sites and to various depths. Subcutaneous or hypodermic (under the skin) Intramuscular (muscle) Intravenous (vein) Intradermal (skin) Intraspinal (spinal column) Intrathecal (spinal fluid) Intracardiac (heart) Intraarticular (joint) Intrasynovial (joint fluid area) Intraocular (eye) NOTE: All parenteral products must be sterile.

Dosage 52

Dosage 52